Company Filing History:
2 out of 3,923 
2 out of 1,975 
Years Active: 2015
Title: David Dong Eun Chang: Innovator in Cancer Treatment
Introduction
David Dong Eun Chang is a notable inventor based in Calabasas, California. He has made significant contributions to the field of pharmaceuticals, particularly in cancer treatment. With a total of 2 patents, his work focuses on innovative combination therapies that target specific cancer pathways.
Latest Patents
Chang's latest patents include groundbreaking pharmaceutical combinations. The first patent involves a combination therapy that includes an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor and an insulin-like growth factor-1 receptor (IGF1R) inhibitor. This combination aims to provide effective treatment options for cancer patients. The second patent also centers on a combination therapy that features a MEK inhibitor and the IGF1R inhibitor. Both patents emphasize methods for treating cancer through the administration of these therapeutically effective combinations.
Career Highlights
Throughout his career, David Chang has worked with prominent companies in the pharmaceutical industry. He has been associated with Novartis AG and Amgen Inc., where he has contributed to various research and development projects. His expertise in the field has allowed him to make significant advancements in cancer therapies.
Collaborations
Chang has collaborated with esteemed colleagues, including Xizhong Huang and Malte Peters. These partnerships have fostered innovation and have been instrumental in the development of his patented therapies.
Conclusion
David Dong Eun Chang is a distinguished inventor whose work in cancer treatment through innovative combination therapies has the potential to change the landscape of oncology. His contributions to the pharmaceutical field are noteworthy and continue to inspire advancements in medical research.